Luminespib (INN,[2] previously known as NVP-AUY922) is an experimental drug candidate for the treatment of cancer.

It was discovered through a collaboration between The Institute of Cancer Research and the pharmaceutical company Vernalis[3] and licensed to Novartis.

Luminespib has shown promising activity in preclinical testing against several different tumor types.

[7][8][9][10] A related compound, NVP-HSP990, was abandoned by Novartis in 2012 after it failed to show efficacy in an early clinical trial.

This antineoplastic or immunomodulatory drug article is a stub.